Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Michelson, D. Articles by Beasley, C. M. Search for Related Content PubMed Citation Articles by Michelson, D. Articles by Beasley, C. M., Jr. Depression DSM Antidepressants

Changes in Weight During a 1-Year Trial of Fluoxetine

OBJECTIVE: Fluoxetine has been associated with weight loss during acute treatment, but no controlled studies of weight change during long-term treatment with fluoxetine or other selective serotonin reuptake inhibitors have been reported. Weights were assessed for patients whose depressive symptoms had disappeared with acute fluoxetine treatment. Patients were then randomly assigned to continuation treatment with fluoxetine or placebo. METHOD: Patients whose illness had remitted after 12 weeks of treatment with fluoxetine, 20 mg/day, were randomly assigned to receive up to 38 weeks of treatment with fluoxetine or placebo. Weight was assessed at each visit. Change in weight was analyzed during the initial 12 weeks of acute treatment and after 14, 26, and 38 weeks. Relationships between weight change and body mass index and between weight change and appetite change were assessed. RESULTS: During the initial 4 weeks of therapy, a mean absolute weight decrease of 0.4 kg was observed for all patients. Among patients who completed 50 weeks of therapy, the mean absolute weight increase during continuation treatment was similar for both the placebo- and fluoxetine-treated groups. Weight increase was not related to initial body mass index but was related to both poor appetite at study entry and to improvement in appetite after recovery. No patients discontinued therapy because of weight gain. CONCLUSIONS: Acute therapy with fluoxetine is associated with modest weight loss. After remission of depressive symptoms, weight gain for patients taking fluoxetine for longer periods is not different from that for patients taking placebo and is most likely related to recovery from depression.

This article has been cited by other articles:

				G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 734 - 750. [Abstract] [Full Text] [PDF]

				G. L. Jensen Drug-Induced Hyperphagia: What Can We Learn From Psychiatric Medications? JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 578 - 581. [Abstract] [Full Text] [PDF]

				K. Demyttenaere and L. Jaspers Review: Bupropion and SSRI-induced side effects J Psychopharmacol, September 1, 2008; 22(7): 792 - 804. [Abstract] [PDF]

				J. DONOGHUE and T. R. HYLAN Antidepressant use in clinical practice: efficacy v. effectiveness The British Journal of Psychiatry, September 1, 2001; 179 (42): s9 - s17. [Abstract] [Full Text] [PDF]

				Prozac Doesn't Cause Weight Gain Journal Watch Women's Health, September 1, 1999; 1999(901): 9 - 9. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us